<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793702</url>
  </required_header>
  <id_info>
    <org_study_id>TESEC-01</org_study_id>
    <secondary_id>EUDRACT No.: 2008-001489-96</secondary_id>
    <nct_id>NCT00793702</nct_id>
  </id_info>
  <brief_title>Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration</brief_title>
  <official_title>An Open Phase I Clinical Trial on the Safety and Risk of Sensitisation by Escalating Doses and Repeated Injections of the rdESAT-6 + rCFP-10 Skin Test Reagent Following Intradermal Administration to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Statens Serum Institut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety of three dose levels (0.01, 0.1 and 1.0 µg) of&#xD;
      the rdESAT-6 + rCFP-10 skin test reagent when injected into healthy adults. The secondary&#xD;
      objective is to assess the risk of sensitisation of 0.01 and 0.1 µg rdESAT-6 + rCFP-10 when&#xD;
      injected twice with time intervals of 6 or 12 weeks to healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic adverse events with onset after the FIRST (0.01, 0.1 and 1.0 µg) or SECOND (0.01 and 0.1 µg) injection</measure>
    <time_frame>onset between the first injection and 28 days after the second injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The diameter of induration at the second injection site measured transversely to the long axis of the forearm</measure>
    <time_frame>72 hours after the second injection</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one injection 1.0 µg rdESAT-6 + rCFP-10</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rdESAT-6 + rCFP-10</intervention_name>
    <description>rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has signed an informed consent&#xD;
&#xD;
          2. Is willing and likely to be able to comply with the trial procedures&#xD;
&#xD;
          3. Is female/male non-black adult ≥ 18 years and ≤ 55 years of age&#xD;
&#xD;
          4. Is healthy according to a medical examination, medical history and laboratory&#xD;
             investigations at inclusion&#xD;
&#xD;
          5. Is prepared to grant authorized persons access to their medical records&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history of tuberculosis or has had a known contact to a person with active&#xD;
             tuberculosis&#xD;
&#xD;
          2. Has a positive QuantiFERON-TB Gold In Tube test result at inclusion&#xD;
&#xD;
          3. Laboratory parameters outside of normal range judged by principal investigator to be&#xD;
             clinically significant and/or abnormal glucose or protein levels in a urine sample at&#xD;
             inclusion&#xD;
&#xD;
          4. Has been in treatment with a product which is likely to modify the immune response&#xD;
             within 3 months prior to the day of inclusion (e.g., immunoglobulin, systemic&#xD;
             corticosteroids, methotrexate, azathioprine, cyclosporine, infliximab or blood&#xD;
             products)&#xD;
&#xD;
          5. Has been vaccinated with a live vaccine within 6 months prior to the day of inclusion&#xD;
             (e.g., MMR, yellow fever, or oral typhoid vaccines)&#xD;
&#xD;
          6. Has a known congenital or acquired immune deficiency&#xD;
&#xD;
          7. Has a disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma,&#xD;
             leukemia, sarcoidosis)&#xD;
&#xD;
          8. Is known to be infected with HIV, HBV or HCV&#xD;
&#xD;
          9. Has a severe ongoing viral or bacterial infection that might affect the cell mediated&#xD;
             immune response at inclusion&#xD;
&#xD;
         10. Has a C-reactive protein (CRP) level &gt; 50 mg/L&#xD;
&#xD;
         11. Has severe scarring, burn, rash, eczema, psoriasis, or any other skin disease at or&#xD;
             near the injection site(s)&#xD;
&#xD;
         12. Has a condition in which repeated blood drawings pose more than minimal risk for the&#xD;
             volunteer, such as haemophilia, other coagulation disorders, or significantly impaired&#xD;
             venous access&#xD;
&#xD;
         13. Is actively participating in another clinical trial or has participated in previous&#xD;
             clinical trials investigating the rdESAT-6 skin test reagent&#xD;
&#xD;
         14. Is pregnant according to urine pregnancy test at inclusion&#xD;
&#xD;
         15. Is a female not willing to use contraceptives or is breastfeeding&#xD;
&#xD;
         16. Has a condition which in the opinion of the investigator is not suitable for&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pernille Nyholm Tingskov</last_name>
    <role>Study Director</role>
    <affiliation>Statens Serum Institut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Epidemiklinikken</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>diagnosis</keyword>
  <keyword>ESAT-6</keyword>
  <keyword>CFP-10</keyword>
  <keyword>skin test</keyword>
  <keyword>Skin test for the diagnosis of tuberculosis infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

